Collection Rapports & synthèses, ouvrage collectif édité par l'INCa, 2011. ,
??pid??miologie du cancer bronchique primitif??: aspects classiques et nouveaut??s, Revue des Maladies Respiratoires, vol.28, issue.8, pp.1048-58, 2011. ,
DOI : 10.1016/j.rmr.2010.12.015
Ministère de la Santé et des Sports. Plan cancer, 2009. ,
ANATOMIE Tome 1 Le tronc. Paris: Médecine-Sciences Flammarion, 1998. ,
Anatomie du poumon humain, EMC - Pneumologie, vol.9, issue.3, pp.1-11, 2012. ,
DOI : 10.1016/S1155-195X(12)50830-3
Les pédicules segmentaires du poumon ,
Expansion Scientifique, 1952. ,
Les pédicules segmentaires du poumon. Tome II poumon gauche ,
Expansion Scientifique, 1955. ,
Survie des patients atteints de cancer en France : étude à partir des données des registres du réseau Francim, BEH, pp.9-1066, 2007. ,
Épidémiologie et facteurs de risque des cancers bronchiques primitifs, EMC, vol.Pneumologie, p.8, 2004. ,
DOI : 10.1016/j.emcpn.2003.10.002
Study of the Aetiology of Carcinoma of the Lung, BMJ, vol.2, issue.4797, pp.1271-86, 1952. ,
DOI : 10.1136/bmj.2.4797.1271
TOBACCO SMOKING AS A POSSIBLE ETIOLOGIC FACTOR IN BRONCHIOGENIC CARCINOMA, Journal of the American Medical Association, vol.143, issue.4, pp.329-365, 1950. ,
DOI : 10.1001/jama.1950.02910390001001
Lung cancer and use of cigarettes : a French case-control study, J Natl Cancer Inst, vol.74, issue.6, pp.1169-75, 1985. ,
Lung cancer and cigarette smoking in Europe: An update of risk estimates and an assessment of inter-country heterogeneity, International Journal of Cancer, vol.11, issue.6, pp.876-87, 2001. ,
DOI : 10.1093/aje/152.1.32
Le point sur l'épidémie de cancer du poumon dû au tabagisme, BEH, pp.19-20211, 2010. ,
Mortality in relation to smoking: 40 years' observations on male British doctors, BMJ, vol.309, issue.6959, pp.901-912, 1994. ,
DOI : 10.1136/bmj.309.6959.901
Mortality in relation to smoking: 50 years' observations on male British doctors, BMJ, vol.328, issue.7455, p.1519, 2004. ,
DOI : 10.1136/bmj.38142.554479.AE
Patterns of Absolute Risk of Lung Cancer Mortality in Former Smokers, JNCI Journal of the National Cancer Institute, vol.85, issue.6, pp.457-64, 1993. ,
DOI : 10.1093/jnci/85.6.457
Les pathologies respiratoires li??es au tabagisme passif, Revue des Maladies Respiratoires, vol.26, issue.6, pp.667-78, 2009. ,
DOI : 10.1016/S0761-8425(09)74696-0
The accumulated evidence on lung cancer and environmental tobacco smoke, BMJ, vol.315, issue.7114, pp.980-988, 1997. ,
DOI : 10.1136/bmj.315.7114.980
Exposure to environmental tobacco smoke and the risk of lung cancer: a meta-analysis, Lung Cancer, vol.27, issue.1, pp.3-18, 2000. ,
DOI : 10.1016/S0169-5002(99)00093-8
Lung cancer and diesel exhaust: A critical review of the occupational epidemiology literature, Critical Reviews in Toxicology, vol.13, issue.3, pp.189-244, 2010. ,
DOI : 10.1080/15298669191365162
Lung cancer and diesel exhaust: an updated critical review of the occupational epidemiology literature, Critical Reviews in Toxicology, vol.6, issue.1, pp.549-98, 2012. ,
DOI : 10.1021/es990903w
URL : https://hal.archives-ouvertes.fr/hal-01263002
Lung Cancer Risk in Painters: A Meta-Analysis, Environmental Health Perspectives, vol.118, issue.3, pp.303-315, 2010. ,
DOI : 10.1289/ehp.0901402.s1
Occupational exposure to polycyclic aromatic hydrocarbons and lung cancer risk: a multicenter study in Europe, Occupational and Environmental Medicine, vol.67, issue.2, pp.98-103, 2010. ,
DOI : 10.1136/oem.2009.046680
Anatomie pathologique des cancers bronchopulmonaires, EMC - Pneumologie, vol.5, issue.2, pp.6-8, 2008. ,
DOI : 10.1016/S1155-195X(08)47943-4
World Healt Organization Classification of Tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart, 2004. ,
Collection Recommandations et référentiels, ouvrage collectif édité par l'INCa, 2011. ,
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours, Journal of Thoracic Oncology, vol.2, issue.8, pp.706-720, 2007. ,
DOI : 10.1097/JTO.0b013e31812f3c1a
The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours, Journal of Thoracic Oncology, vol.2, issue.8, pp.694-705, 2007. ,
DOI : 10.1097/JTO.0b013e31812d05d5
Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials, Annals of Oncology, vol.15, issue.12, pp.1782-1791, 2004. ,
DOI : 10.1200/JCO.1996.14.1.127
Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis, JNCI Journal of the National Cancer Institute, vol.47, issue.1, pp.847-57, 2007. ,
DOI : 10.1016/j.lungcan.2004.10.014
Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.22, issue.19, pp.3852-3861, 2004. ,
DOI : 10.1200/JCO.2004.02.109
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes, Lung Cancer, vol.47, issue.1 ,
DOI : 10.1016/j.lungcan.2004.10.014
Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial, Lung Cancer, vol.43, issue.2, pp.183-94, 2004. ,
DOI : 10.1016/j.lungcan.2003.09.001
Paclitaxel???Carboplatin Alone or with Bevacizumab for Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.355, issue.24, pp.2542-50, 2006. ,
DOI : 10.1056/NEJMoa061884
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non???Small-Cell Lung Cancer: AVAiL, Journal of Clinical Oncology, vol.27, issue.8, pp.1227-1261, 2009. ,
DOI : 10.1200/JCO.2007.14.5466
Biological and clinical implications of EGFR mutations in lung cancer, International Journal of Clinical Oncology, vol.11, issue.Suppl 1, pp.190-198, 2006. ,
DOI : 10.1053/sonc.2002.35642
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer, New England Journal of Medicine, vol.361, issue.10, pp.958-67, 2009. ,
DOI : 10.1056/NEJMoa0904554
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials, Clinical Cancer Research, vol.15, issue.16, pp.5267-73, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-0888
Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis, Journal of Cancer Research and Clinical Oncology, vol.2, issue.2, pp.1483-93, 2009. ,
DOI : 10.4161/cc.4.10.2105
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non-Small Cell Lung Cancer with EGFR Mutations, Clinical Cancer Research, vol.15, issue.13, pp.4493-4501, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-0391
Décret n° 2005-1023 du 24 août 2005 relatif au contrat de bon usage des médicaments et des produits et prestations mentionné à l'article L. 162-22-7 du code de la sécurité sociale (troisième partie : Décrets) [en ligne], Disponibilité sur Internet, 2005. ,
Référentiel de bon usage de la liste hors GHS : cancers bronchiques et mésothéliomes pleuraux malins [en ligne]. Mars, Disponibilité sur Internet, 2012. ,
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL), Annals of Oncology, vol.3, issue.3, pp.1804-1813, 2010. ,
DOI : 10.1016/j.ccr.2008.08.001
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.22, issue.11, pp.2184-91, 2004. ,
DOI : 10.1200/JCO.2004.11.022
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer, Cancer, vol.20, issue.11, pp.2449-56, 2005. ,
DOI : 10.4161/cbt.1.5.223
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial, Clin Cancer Res, vol.11, issue.2, pp.690-696, 2005. ,
phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group, J Clin Oncol, vol.21, issue.16, pp.3016-3040, 2003. ,
Docetaxel in Second-Line Treatment of non???small-Cell Lung Cancer, Clinical Lung Cancer, vol.3, issue.2, pp.23-28, 2002. ,
DOI : 10.3816/CLC.2002.s.010
A phase II study of combination chemotherapy with docetaxel and carboplatin for patients with advanced or metastatic non-small cell lung cancer, Anticancer Res, vol.26, issue.5B, pp.3723-3731, 2006. ,
Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial, J Clin Oncol, vol.23, issue.13, pp.2937-2982, 2005. ,
Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer, British Journal of Cancer, vol.16, issue.Suppl 2, pp.795-802, 2003. ,
DOI : 10.1200/JCO.1998.16.5.1948
Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: A Phase I/II study with 5 years??? follow-up, Lung Cancer, vol.50, issue.1, pp.97-105, 2005. ,
DOI : 10.1016/j.lungcan.2005.05.010
Phase III Trial Comparing Docetaxel and Cisplatin Combination Chemotherapy With Mitomycin, Vindesine, and Cisplatin Combination Chemotherapy With Concurrent Thoracic Radiotherapy in Locally Advanced Non???Small-Cell Lung Cancer: OLCSG 0007, Journal of Clinical Oncology, vol.28, issue.20, pp.3299-306, 2010. ,
DOI : 10.1200/JCO.2009.24.7577
Référentiel de bon usage de la liste hors GHS : cancers bronchiques et mésothéliomes pleuraux malins, Disponibilité sur Internet, 2009. ,
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer, Annals of Oncology, vol.1, issue.3, pp.540-547, 2010. ,
DOI : 10.1002/1097-0142(197402)33:2<492::AID-CNCR2820330225>3.0.CO;2-O
Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.27, issue.34, pp.5808-5823, 2009. ,
DOI : 10.1200/JCO.2009.21.9766
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group, Annals of Oncology, vol.19, issue.1, pp.115-137, 2008. ,
DOI : 10.1093/annonc/mdm430
Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity, British Journal of Cancer, vol.16, issue.3, pp.283-292, 2007. ,
DOI : 10.1016/S0169-5002(03)00233-2
Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non???Small-Cell Lung Cancer: A Phase III Randomized Trial, Journal of Clinical Oncology, vol.20, issue.17, pp.3578-85, 2002. ,
DOI : 10.1200/JCO.2002.12.112
Randomized Phase III Study of Gemcitabine and Vinorelbine Versus Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer: From the German and Swiss Lung Cancer Study Group, Journal of Clinical Oncology, vol.22, issue.12, pp.2348-56, 2004. ,
DOI : 10.1200/JCO.2004.10.576
Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non???Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial, Journal of Clinical Oncology, vol.21, issue.17, pp.3207-3220, 2003. ,
DOI : 10.1200/JCO.2003.12.038
Référentiel de bon usage de la liste hors GHS : cancers bronchiques et mésothéliomes pleuraux malins [en ligne]. Décembre, Disponibilité sur Internet, 2011. ,
Membres du comité éthique et cancer) Avis n°17 du 30 septembre 2011 « Du bon usage des molécules onéreuses en cancérologie et avis sur les choix inhérents aux contraintes imposées par le coût de ces molécules, Bulletin Ethique et cancer. déc, vol.9, pp.4-5, 2011. ,